Who gets to pick the new name for the American Bank Center?
(This story was updated to add new information and because an earlier version included an inaccuracy.)
Correction: A previous version of this story misstated the timeline by which the city of Corpus Christi and OVG need to come to an agreement over the naming rights for the American Bank Center.
Whose name will be emblazoned on what is now the American Bank Center has started a renewed round of debate — but one that remains centered on whether the name the building ultimately bears is Thomas J. Henry Law.
In news releases issued June 4 and June 5, the high-profile personal injury attorney suggested that his offer for the naming rights — $1.25 million annually for 10 years — made the most sense.
Henry has made his interest in the naming rights of the American Bank Center publicly known for more than a year, as well as his proposed bid — in one news release describing the process as 'mired in needless delay and political interference.'
'There is no other company that has offered—nor is willing or able to offer—a deal of comparable value to the taxpayers,' the news release states. 'Every month this process is delayed is another month of lost revenue for the hardworking families of Corpus Christi.'
Henry also suggested in the news release that there were 'growing concerns of political bias obstructing a significant public-private opportunity.'
In a message to the Caller-Times, Mayor Paulette Guajardo wrote that the city is 'committed to a fair naming process,' describing the American Bank Center as 'a cornerstone of the city's cultural and economic vibrancy.'
The contract between the city and OVG, the American Bank Center's management company, calls for OVG to manage the naming rights process with a final decision 'based on feedback and collaboration between OVG, City Council, and City staff,' she wrote.
'Next week, we expect that feedback to be given,' Guajardo wrote in the June 5 message. 'OVG has a process committed to a transparent and thorough evaluation considering all proposals fairly. Any assertions otherwise are patently false and designed to receive media attention.'
The dispute over the naming rights for the landmark building has taken on multiple fronts, to include the process in which a decision is reached and who makes the decision.
OVG representatives did not immediately respond to a message sent by the Caller-Times, but city officials confirmed that Henry's is one of two proposals for the naming rights.
Information was not immediately available about the second company or its proposal amount.
American Bank has sponsored the taxpayer-owned entertainment venue on Shoreline Boulevard for about 20 years but announced in April 2024 its intent to end the partnership.
It was initially thought the center would shed its American Bank name in September 2024.
There have been several extensions since then, City Manager Peter Zanoni told the Caller-Times.
In a memo, he wrote that staff was in process of scheduling meetings between City Council members and OVG representatives.
They are intended 'to ensure OVG is available to answer questions from City Council Members interested in this topic' and to allow city officials 'to ask more detailed questions about their naming rights process, recommendations, alternatives, and next steps,' Zanoni wrote in the memo.
'Feedback from Council Members is a crucial part of OVG's decision-making process for the naming rights.'
He told the Caller-Times that OVG engaged with about 100 entities over the past two years as part of its naming rights process, with less than a dozen considered to be serious contenders.
May 31 was the last call for proposals, Zanoni said, adding that the city and OVG need to come to an agreement in the near future.
Options described by Zanoni include: selecting a naming rights partner, starting the naming rights process over again, requesting an additional extension with American Bank, forgoing a name entirely or picking a general name for the venue that is not associated with a naming rights partner.
The current contract with American Bank expires at the end of August, he added, at which point there will be a 30-day timeline in which signage must be removed.
While some council members have voiced support for Henry's offer — City Councilman Eric Cantu issued a news release fully backing the attorney and 'a transformational deal for a city asset that needs it' — others have questioned what they consider to be a push for a potentially hurried process.
'It would seem to me that whatever is the best solution today will also be the best solution next week and next month,' said City Councilman Mark Scott. 'So I'm fascinated by what I perceive to be as pressure to rush to a decision.'
Henry's bid far outweighs the other proposal, Cantu said, asserting that politics are obstructing moving forward with the process. In his news release, he pointed out that the 'city of Corpus Christi is facing a serious budget shortfall.'
The deficit was last estimated to be about $7 million.
'It's just sad — this man has money from his business and wants to invest in Corpus Christi,' Cantu told the Caller-Times. 'We should be happy that he wants to invest in Corpus Christi and give us that much money to put his name on a building.'
Henry's news release named Guajardo, Scott and City Councilman Roland Barrera as continuing 'to stand in the way of progress.'
Barrera asserted that Henry is 'utilizing the press to try to manipulate the narrative and manipulate negotiations,' in part referencing statements in Henry's news release accusing council members of 'interference.'
'I just don't know how you negotiate in good faith with a partner that's actually painting themselves as the victim and (making) statements like that,' he said. 'It's just a nonstarter for me.'
The exact balance of the roles that OVG and the City Council play in determining the naming rights wasn't immediately clear June 5; however, the management company wrote in an email to the Caller-Times last year that it was 'leading the selection process for the naming rights partner, and the decision will be made in collaboration with the City of Corpus Christi.'
Cantu wants the discussion about the naming rights to be held publicly in the June 10 council meeting, and has criticized the contract with OVG, asserting the decision should be solely the council's.
Scott said he was seeking to be 'fully informed and make sure the council's fully informed of all the relative data points that lead to a decision.'
'It's not obstruction,' he said. 'I think it's just making sure that we make the right decision with the right information.'
More: American Bank is parting ways with American Bank Center
This article originally appeared on Corpus Christi Caller Times: Who gets to pick the new name for the American Bank Center?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Yahoo
28 minutes ago
- Yahoo
Christina Bohannan makes third run for Iowa's 1st Congressional District
Jun. 21—History shows that just because a candidate makes multiple attempts to win an election doesn't mean they can't eventually pull through. U.S. Rep. Mariannette Miller-Meeks lost a number of times to Dave Loebsack before winning Iowa's 1st Congressional District seat in a close 2020 election. Now her past Democratic challenger, Christina Bohannan, is attempting the same thing for the 2026 election cycle, provided she is the favorite in the primary. On June 17, Bohannan announced her campaign to take on Miller-Meeks once again. In a press release, her campaign said Bohannan nearly defeated Miller-Meeks in 2024 — less than 800 votes decided the election — and that the Democrat "outworked, outraised and outmatched her." Bohannan said, "Mariannette Miller-Meeks has had three terms in Congress — three chances to do right by the people of Iowa. Instead, she has taken over $4 million from corporate special interests and done nothing but vote their way. And she has put partisan politics over Iowans again and again. From cutting billions of dollars from Medicaid in the Trump Administration's One Big Beautiful Bill, to siding with DOGE's cuts to Social Security and enabling unelected, unaccountable billionaires like Elon Musk, Bohannan said the Republican congresswoman has forgotten about her constituents. "It's time someone put Iowa first," Bohannan said. Bohannan went on to say Miller-Meeks needs to explain "why she keeps putting Washington special interests first." The Democratic challenger claimed Miller-Meeks supported Trump's One Big Beautiful Bill, repeatedly voted for cost-increasing tariffs and is a member of the DOGE Caucus. Bohannan previously worked as an engineer and taught at the University of Iowa College of Law for 20 years. She also worked as an elected legislator for the Iowa House, defeating a 20-year incumbent in District 85. Bohannan is running for Congress because she believes in a government that works for the people. In May, another Democrat announced he would be running for Iowa's 1st Congressional District. Bob Krause, a former legislator who also tried running for U.S. Senate, announced his campaign with the slogan "Flip The House With Krause." Krause said Miller-Meeks votes "like Trump's rubber stamp." Travis Terrell, a Democrat from Johnson County, also announced his bid for Iowa's 1st Congressional District race. His campaign page on Facebook notes he is a working-class, New Deal Democrat fighting for healthcare, fair wages and a government that serves other working-class people and not billionaires. In addition to Miller-Meeks likely running for the seat, fellow Republican and former primary challenger David Pautsch announced in February that he would also be running for the seat. Pautsch touts himself as a MAGA Republican. He has been critical of Miller-Meeks, saying she is not conservative enough.
